INM · NASDAQ
InMed Pharmaceuticals Inc.
$1.58 +0.11 (+8.27%)
Company overview
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream in a second Phase I clinical trial for the treatment of epidermolysis bullosa. InMed is also developing INM-088, which is in preclinical studies for the treatment of glaucoma, and INM-405 for the treatment of pain. In addition, the company engages in developing cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, InMed works on IND-enabling pharmacology and preclinical toxicology studies, as well as IntegraSyn, an integrated biosynthesis-based manufacturing approach for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $8.7M
- Employees
- 13
- Headquarters
- Vancouver, BC
- Website
- inmedpharma.com
- CEO
- Eric A. Adams Chem.
- Listed
- May 5, 2014
- P/E
- -0.00
- Dividend yield
- 0.00%
Company financials
- Revenue
- $4M
- Gross profit
- $1.2M
- Operating income
- -$9.9M
- EBITDA
- -$9.4M
- Net income
- -$9.9M
- EPS
- -$1,142.54
- Total assets
- $9.1M
- Total debt
- $420,147
- Gross margin
- 30.44%
- Net margin
- -246.41%
- Earnings yield
- -72,312.66%
No annual segmentation.
No geographic segmentation.
INM
1D
NASDAQ
O1.42H1.59L1.42C1.57+0.13 (+8.68%)Vol71.71K